N-[1-tert-Butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-2-chlorobenzamide

Catalog No. :
ACLVES521
CAS No. :
477859-18-0
Molecular Formula :
C23H22ClN5O
Molecular Weight :
419.92

IUPAC Name:N-(1-(tert-butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-chlorobenzamide

N-[1-tert-Butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-2-chlorobenzamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$324.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[1-tert-Butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-2-chlorobenzamide
IUPAC NameN-(1-(tert-butyl)-3-(p-tolyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-chlorobenzamide
MDL No.MFCD01814673
Molecular FormulaC23H22ClN5O
Molecular Weight419.92
SMILESO=C(NC1=C2C(N(C(C)(C)C)N=C2C3=CC=C(C)C=C3)=NC=N1)C4=CC=CC=C4Cl
InChI KeyKJEKAEJZMAQUBE-UHFFFAOYSA-N
SynonymN-[1-(TERT-BUTYL)-3-(4-METHYLPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-2-CHLOROBENZENECARBOXAMIDE;N-[1-tert-butyl-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-2-chlorobenzamide;Benzamide, 2-chloro-N-[1-(1,1-dimethylethyl)-3-(4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-
CAS No.477859-18-0

Synthetic Route by SureRoute

1. ACLVES521 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACMSUO314 route compound structure diagram
    ACMSUO314172889-26-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLVES521 route product structure diagram
    ACLVES521477859-18-0
Inquiry

2. ACLVES521 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACYXCW831 route compound structure diagram
    ACYXCW8315720-05-8 In Stock
  4. Then
  5. ACLVES521 route product structure diagram
    ACLVES521477859-18-0
Inquiry

Comments (0)